Hanxi Yi

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 7

Top Topics

Pseudomonas Aeruginosa

Acute Kidney Injury

Top Venues

Antimicrobial agents and chemotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Xiaonan Zhang, Yan Wang, Sanwang Li, Feifan Xie, Hanxi Yi
Simulated drug disposition in critically ill patients to evaluate effective PK/PD targets for combating Pseudomonas aeruginosa resistance to meropenem. Antimicrobial agents and chemotherapy 68 (3) (2024)
Xiaonan Zhang, Yan Wang, Sanwang Li, Feifan Xie, Hanxi Yi
Simulated drug disposition in critically ill patients to evaluate effective PK/PD targets for combating Pseudomonas aeruginosa resistance to meropenem. Antimicrobial agents and chemotherapy 68 (3) (2024)
Xiaonan Zhang, Yan Wang, Sanwang Li, Feifan Xie, Hanxi Yi
Simulated drug disposition in critically ill patients to evaluate effective PK/PD targets for combating Pseudomonas aeruginosa resistance to meropenem. Antimicrobial agents and chemotherapy (2024)
Xiaonan Zhang, Yan Wang, Sanwang Li, Feifan Xie, Hanxi Yi
Simulated drug disposition in critically ill patients to evaluate effective PK/PD targets for combating Pseudomonas aeruginosa resistance to meropenem. Antimicrobial agents and chemotherapy 68 (3) (2024)
Xiaonan Zhang, Yan Wang, Sanwang Li, Feifan Xie, Hanxi Yi
Simulated drug disposition in critically ill patients to evaluate effective PK/PD targets for combating Pseudomonas aeruginosa resistance to meropenem. Antimicrobial agents and chemotherapy 68 (3) (2024)
Xiaonan Zhang, Yan Wang, Sanwang Li, Feifan Xie, Hanxi Yi
Simulated drug disposition in critically ill patients to evaluate effective PK/PD targets for combating Pseudomonas aeruginosa resistance to meropenem. Antimicrobial agents and chemotherapy 68 (3) (2024)
Xiaonan Zhang, Yan Wang, Sanwang Li, Feifan Xie, Hanxi Yi
Simulated drug disposition in critically ill patients to evaluate effective PK/PD targets for combating Pseudomonas aeruginosa resistance to meropenem. Antimicrobial agents and chemotherapy 68 (3) (2024)